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Introduction: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment
extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional
therapy. In the RCTs, approximately 40% of patients treated with the approved dose saw complete response
(CR) of at least one tophus. Here we describe the temporal course of tophus resolution, total tophus burden in
patients with multiple tophi, tophus size at baseline, and the relationship between tophus response and urate-
lowering efficacy.
Methods: Baseline subcutaneous tophi were analyzed quantitatively using computer-assisted digital images in
patients receiving pegloticase (8 mg biweekly or monthly) or placebo in the RCTs, and pegloticase in the OLE.
Tophus response, a secondary endpoint in the trials, was evaluated two ways. Overall tophus CR was the
proportion of patients achieving a best response of CR (without any new/enlarging tophi) and target tophus
complete response (TT-CR) was the proportion of all tophi with CR.
Results: Among 212 patients randomized in the RCTs, 155 (73%) had ≥1 tophus and 547 visible tophi were
recorded at baseline. Overall tophus CR was recorded in 45% of patients in the biweekly group (P = 0.002 versus
placebo), 26% in the monthly group, and 8% in the placebo group after six months of RCT therapy. TT-CR rates at
six months were 28%, 19%, and 2% of tophi, respectively. Patients meeting the primary endpoint of sustained
urate-lowering response to therapy (responders) were more likely than nonresponders to have an overall tophus
CR at six months (54% vs 20%, respectively and 8% with placebo).
Both overall tophus CR and TT-CRs increased with treatment duration in the OLE, reaching 70% (39/56) of patients
and 55% (132/238) of target tophi after one year of treatment in patients receiving pegloticase during both the
RCTs and OLE. At that time point, more tophi had resolved in responders (102/145 or 70% of tophi) than
nonresponders (30/93; 32%).
Conclusions: Pegloticase reduced tophus burden in patients with refractory tophaceous gout, especially those
achieving sustained urate-lowering. Complete resolution of tophi occurred in some patients by 13 weeks and in
others with longer-term therapy.
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Refractory gout refers to the condition of a population of
patients with symptomatic gout in whom treatment has
failed to maintain a serum uric acid (SUA) level less than
6 mg/dl with oral urate-lowering therapies (ULTs) and
appropriate medical management [1,2]. Patients with re-
fractory gout are at risk for progressive urate crystal de-
position disease, characterized by frequent attacks of
acute gouty arthritis, gouty arthropathy and enlarging
tophi, which are often associated with chronic pain, im-
pairment of physical function and compromised health-
related quality of life [1,3,4].
The tophus, a cardinal feature of chronic gout, is a
mass of urate crystals embedded in fibrous and inflam-
matory tissue. Tophi contribute to gouty joint destruc-
tion and deformity and may undergo acute or chronic
ulceration, erode adjacent bone, cause pressure effects
on surrounding tissues and organs, interfere with joint
function or become infected [1,5-9]. Once established,
tophi do not regress or resolve unless the extracellular
urate saturation that supports urate crystal deposi-
tion (reflected by hyperuricemia or SUA in excess of
6.8 mg/dl) is reversed and subsaturating urate levels are
maintained. Achievement and maintenance of SUA in a
range less than 6.0 mg for months to years does, how-
ever, promote dissolution of urate crystal deposits and
prevent further crystal deposition in tissues [10]. Rates
of resolution of tophaceous deposits appear to be
dependent on the extent of urate-lowering [11,12]. Fur-
thermore, tracking the course of tophus size or number
over time during treatment provides a means by which
to assess the clinical benefit of urate-lowering agents
and even their disease-modifying capability.
With currently prescribed doses of available oral ULTs,
tophus resolution commonly requires many months to
years [13,14]. Patients with tophaceous gout and chronic
pain, functional impairment, compromised quality of life
or complications of gouty deformity have a compelling
need for rapid reversal of their tophaceous disease.
Pegloticase is a mammalian PEGylated recombinant
uricase approved in the United States for the treatment
of chronic gout refractory to conventional therapy and
in the European Union for severe debilitating chronic
tophaceous gout in patients who may also have erosive
joint involvement. The efficacy of pegloticase in reducing
and maintaining plasma uric acid (PUA) levels substan-
tially below 6 mg/dl was initially demonstrated in a ran-
domized, open-label phase II study [2]. Two patients in
the phase II trial were documented with marked reduc-
tions in tophus size after treatment with pegloticase for
12 weeks, which coincided with sustained decreases in
PUA to less than 2 mg/dl [15]. On the basis of this un-
precedented finding, tophus reduction or resolution was
evaluated as a key secondary endpoint in two replicate,randomized, six-month, double-blind, placebo-controlled
phase III trials of pegloticase in patients with chronic gout
refractory to conventional therapy. The primary results of
these randomized controlled trials (RCTs) have been repor-
ted previously [16]. This paper provides a detailed analysis
of the tophus response to pegloticase in the RCT popula-
tion and in a subsequent open-label extension (OLE) study
enrolling the majority (96%) of RCT completers.
Methods
Patients
Eligible patients were ages 18 years or older, had baseline
SUA levels of 8 mg/dl or higher and at least one of the
following clinical features: three or more self-reported
gout flares during the previous eighteen months, one or
more tophi or gouty arthropathy. They also had con-
traindications for or intolerance to treatment with allo-
purinol (82%; 174 of 212 patients) or a failure to
achieve a normal SUA after at least three months of
treatment with the maximum medically appropriate
dose of allopurinol (the only xanthine oxidase inhibi-
tor approved during the trials). Key exclusion criteria
included glucose-6-phosphate dehydrogenase deficiency,
pregnancy, unstable angina, uncontrolled cardiac arrhyth-
mia, uncompensated congestive heart failure, uncontrolled
hypertension (blood pressure higher than 150/95 mmHg
on medication), ongoing maintenance dialysis or a history
of solid organ transplant.
Trial design and randomization
The design of the replicate RCTs has been reported pre-
viously [16]. Briefly, eligible patients were randomized in
a 2:2:1 ratio to receive intravenous infusions of 8 mg
pegloticase every two weeks (biweekly treatment), 8 mg
of pegloticase alternating with placebo (monthly treat-
ment) or placebo at each infusion for twenty-four weeks.
Randomization was stratified based upon the presence
or absence of tophi. Patients receiving ULT at the time
of screening underwent a one-week washout period. All
patients received prophylaxis for both gout flares and in-
fusion reactions [16].
The primary efficacy endpoint in the RCTs was the
proportion of PUA responders in the pegloticase-treated
versus placebo-treated groups, with response defined as
patients who maintained PUA level less than 6 mg/dl for
80% or more of the time during months 3 and 6. Pa-
tients who discontinued treatment prematurely for any
reason were deemed PUA nonresponders.
Patients who completed treatment in either of the
RCTs were eligible to participate in an OLE study. At
the patient’s final visit in the RCT, while still blinded to
treatment assignment and UA response, the investiga-
tor and patient decided whether pegloticase would be
administered biweekly or monthly during the OLE study.
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biweekly to monthly) was allowed once after week 25 of
the OLE and a second time after the RCT results were
unblinded. The OLE study was initially designed as a
12-month study. Protocol amendments allowed treat-
ment with pegloticase for a maximum of 31 months.
The trial protocols were approved by a central institu-
tional review board (IntegReview, Austin, TX, USA) and
local institutional review boards, and informed consent
and Health Insurance Portability and Accountability Act
of 1996 documentation were obtained prior to any
study-related procedures.
Tophus assessment
Tophus assessment was conducted using Computer-
Assisted Photographic Evaluation in Rheumatology
(CAPER) methodology [17]. Two assessments (overall
tophus complete response (CR) and target tophus CR)
were prespecified as secondary efficacy endpoints in the
RCTs and as secondary clinical outcomes in the OLE
study. Each study site was supplied with a calibrated
digital camera, digital media storage cards, preprinted
templates for hand and foot photography and a light
stand. A designated individual was trained and then as-
sumed responsibility for taking all photographs at each
site. Photographs of the hands and feet were obtained
for all patients at baseline. Photographic evaluation was
repeated at weeks 13, 19 and 25 of the RCTs and at
weeks 13, 25, 53, 77 and 101 of the OLE study (for pa-
tients with tophi who remained in the trials) using the
same views of the tophus sites identified at baseline. Ad-
ditional serial photographs of up to two other anatomic
regions were taken at the discretion of the investigator
based on additional tophi identified at the baseline visit.
Photographs on digital media cards were sent to
RadPharm (Princeton, NJ, USA), where central readers
(board-certified rheumatologist and internist), who were
blinded to treatment assignment, evaluated the photo-
graphs prospectively and identified sites of tophi present
at the start of treatment. Central readers chose up to
seven target tophi (five measurable tophi and two un-
measured tophi) for each patient for assessment through-
out the study. Tophi were considered “measurable” if they
had distinguishable borders 5 mm or larger in the longest
dimension at baseline. Tophi were considered “unmea-
surable” if they could not be measured accurately because
of their location, shape or other factors, but could be
assessed qualitatively. To be included for assessment, un-
measured tophi were approximated to be 10 mm or
greater at the longest dimension.
The size of each target tophus was measured using
digital photographs and MedStudioW image analysis soft-
ware (Megasoft, Ltd, Hyderabad, India). Reading was
performed using a sequential locked-read format wherebythe reader could neither make changes to past time points
nor view subsequent time points. For each measurable
target tophus, size was determined in two dimensions
with electronic calipers using the diameter and the longest
width perpendicular to the diameter. Response to treat-
ment was categorized on the basis of change from baseline
as complete response (CR; 100% decrease in area of the
tophus), marked response (MR; 75% or greater to less
than 100% decrease), partial response (PR; 50% or greater
to less than 75% decrease), stable disease (SD; less than
50% decrease to less than 25% increase) and progressive
disease (PD; 25% or greater increase). For each unmea-
sured target tophus, response to treatment was semiquan-
titatively assessed on the basis of the impression of the
central reader, and response was categorized as CR, im-
proved, SD or PD.
Tophus resolution was a secondary endpoint in the
RCTs. The principal assessment was the proportion of
patients achieving a tophus CR, defined as complete
resolution of at least one tophus without development of
new tophi or progressive enlargement of any other to-
phus. This measurement of a patient’s single overall best
tophus response was intended to control for patients
with multiple tophi and varying responses (Figure 1). If
any new or progressing tophi were recorded at any time
during the study, the final overall tophus response for
that patient was PD. A second measure of tophus reso-
lution was based on the total number of photographic-
ally identified baseline tophi. Target tophus CR (TT-CR)
was defined as 100% decrease in the area of the tophus
and is reported as the number or proportion of all base-
line tophi with CR at the specific study visit.
Statistical analysis
The two tophus assessment endpoints are presented as
pooled data for the modified intent-to-treat (mITT) popu-
lation in the RCTs, which comprised all randomized pa-
tients who received at least one dose of study medication
and had at least one postdose observation. Only patients
with tophi were included in these analyses (tophus-
evaluable population). The number or proportion of pa-
tients with overall best response of CR was compared for
each pegloticase dosing group versus the placebo group
using Fisher’s exact test. A similar analysis was applied to
the number of tophi showing CR for the TT-CR endpoint.
The overall tophus CR was further analyzed according to
the patient’s PUA response, which was the predefined pri-
mary endpoint of the RCTs (lower than 6 mg/dl for 80%
of the time during months 3 and 6).
Results
Baseline tophus status
The mITT population included 212 patients with a
mean gout duration of 15 years. From among these
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Figure 1 Illustration of a hypothetical patient showing the target tophus responses and overall tophus response. The diagram shows
the tophus scoring system for a sample patient with four baseline tophi (three measurable and one unmeasurable). Tophus area was defined for
each measurable tophus using the longest dimension and its perpendicular axis. The circle marks the unmeasurable tophus. Each baseline target
tophus was rescored at all subsequent study visits. The patient illustrated in the figure had a best “overall” response of complete response (CR)
because the patient had at least one target tophus response of CR and no new or progressing tophi at any time during the study. PR, partial
response; SD, stable disease.
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tophus (Table 1). Baseline characteristics for tophi were
well-balanced across the three treatment arms of the
RCTs, and no differences were noted in baseline demo-
graphics for patients with and without tophi (Table 2).
During the RCTs, 21 patients showed a new incident to-
phus (all 21 patients also had baseline tophi). New tophi
were seen in 6% (4 of 62), 11% (7 of 64) and 35% (10 of
29) of patients receiving biweekly pegloticase, monthly
pegloticase and placebo treatment, respectively.
Overall tophus complete response
At each time point, a significantly higher proportion of
patients treated with biweekly pegloticase achieved CR
compared with placebo (P ≤ 0.011) (Table 3). By the first
postbaseline assessment in the RCTs (13 weeks), 22% of
patients treated with biweekly pegloticase had attained
an overall tophus CR, compared with 0% of patients inthe placebo group (P = 0.011). At the final visit, 40% of
patients had achieved a best response of CR compared
with 7% in the placebo group (P = 0.002). Although a
higher proportion of patients treated with monthly
pegloticase also achieved an overall tophus CR com-
pared to placebo-treated patients at each time point,
these differences did not reach statistical significance
(Table 3).
Target tophus complete response
Fifty-seven (25%) of two hundred twenty-nine baseline
target tophi in the biweekly pegloticase group achieved
CR as assessed at the final (six-month) RCT study visit
(Table 4). In comparison, TT-CR was achieved in 30
(15%) of 201 target tophi with monthly pegloticase and
in 2 (2%) of 117 target tophi with placebo treatment.
Photographs of CRs in patients treated with pegloticase
biweekly are shown in Figure 3.
64 randomized
to pegloticase
q4 weeks
262 patients screened
225 patients randomized
212 enrolled in RCTs GOUT 1 and 2
155 had baseline tophi
42 entered the OLE study 26 entered the OLE study45 entered the OLE study
29 randomized
to placebo
62 randomized
to pegloticase
q2 weeks
26 completed RCTs
3 withdrawn
1 Adverse event
1 Lost to follow-up
1 Withdrew consent
46 completed RCTs
16 withdrawn
10 Adverse event
2 Death
4 Withdrew consent
45 completed RCTs
     19 withdrawn
11 Adverse event
1 Death
1 Lost to follow-up
1 Non-compliant
5 Withdrew consent
Figure 2 Consolidated Standards of Reporting Trials Statement (CONSORT) diagram for the pooled tophus-evaluable population. This
population flowchart shows the disposition of all patients with baseline tophi pooled from the two randomized, placebo-controlled trials of
pegloticase known as GOUT 1 and GOUT 2. OLE, open-label extension; RCT, randomized controlled trial.
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the randomized trials
Tophus responses were analyzed on the basis of PUA re-
sponder status. Forty-two percent of patients in the bi-
weekly pegloticase group and thirty-five percent of those
in the monthly pegloticase group met the primary end-
point of the RCT and qualified as PUA responders [16].
Overall, tophus CR occurred more frequently at the six-
month visit among PUA responders than among nonre-
sponders: 62% (13 of 21 patients) versus 26% (5 of 19
patients) in the biweekly pegloticase group and 44%
(7 of 16 patients) versus 15% (4 of 26 patients) in the
monthly pegloticase group. When evaluated by response
status and independent of dosing regimen, CR was doc-
umented in 54% of responders (20 of 37 patients) and in
20% of nonresponders (9 of 45 patients) after six months
of RCT treatment.Table 1 Frequency and characteristics of baseline tophi for p
Characteristics Peglot
Patients with one or more baseline tophi, n (%)
Total number of measurable baseline tophi
Median target area of measurable target tophi, mm2 (range) 378Tophus evaluation during open-label extension study
A total of 113 patients with tophi at the baseline
assessment of the RCTs entered the OLE study, in-
cluding 45 patients from the biweekly pegloticase
group, 42 patients from the monthly pegloticase
group and 26 patients from the placebo group. Pa-
tients in the OLE study were categorized according
to their treatment regimen and response status in the
RCTs (Table 5).
The proportion of patients with an overall response of
CR and the proportion of tophi with TT-CR increased
with treatment duration in the OLE study, reaching
(39 (70%) of 56 patients and 132 (55%) of (238) of
target tophi after one year of treatment in patients re-
ceiving pegloticase during both studies. At the final
OLE study visit, among patients randomized to the
biweekly dose, overall tophus CR was achieved inatients in the randomized trials
icase biweekly Pegloticase monthly Placebo
(n = 85) (n = 84) (n = 43)
62 (73) 64 (76) 29 (67)
159 142 83
(25 to 4,080) 377 (25 to 10,625) 460 (30 to 6,230)
Table 2 Baseline characteristics for patients with and
without subcutaneous tophia
Demographics Patients with
baseline tophi
Patients without
baseline tophi
(n = 155) (n = 57)
Males, n (%) 126 (82) 47 (81)
Whites, n (%) 106 (68) 37 (65)
Mean age, years (±SD) 56.7 (13.7) 51.9 (14.4)
Mean BMI, kg/m2 (±SD) 31.3 (6.6) 36.7 (8.6)
Mean baseline PUA, mg/dl (±SD) 9.8 (2.9) 9.4 (3.3)
aBMI, body mass index; PUA, plasma uric acid.
Table 4 Individual target tophus response categories at
patient’s final visit in the randomized trialsa
Categories Pegloticase
biweekly
Pegloticase
monthly
Placebo
(n = 62) (n = 64) (n = 29)
Total number of tophib 229 201 117
Response category, n (%)
CR 57 (25) 30 (15) 2 (2)
PR or MR 49 (21) 33 (16) 12 (10)
SD 111 (49) 121 (60) 89 (76)
PD 1 (0.4) 1 (0.5) 3 (3)
Unable to evaluate 11 (5) 16 (8) 11 (9)
aCR, complete response; MR, marked response; PD: progressive disease;
PR, partial response; SD: stable disease. bTotal tophi includes both measurable
and unmeasurable tophi.
Baraf et al. Arthritis Research & Therapy 2013, 15:R137 Page 6 of 10
http://arthritis-research.com/content/15/5/R13783% of RCT responders (19 of 23 patients) compared
with 25% of RCT nonresponders (4 of 16 patients).
Comparable results were found in the analysis of
TT-CR (Table 5). For all patients in the OLE study,
overall tophus CR was achieved in 60% of patients
(56 of 94) and the TT-CR was 53% (207 of 390 target
tophi) at the final visit. Among responders to
pegloticase in the RCTs, 79% (123 of 156) of target
tophi had resolved (compared with 27% in nonre-
sponders; 35 of 129) by the patient’s final visit of the
OLE study. Among patients initially randomized to
placebo in the RCTs, 13 (62%) of 21 patients had an
overall tophus CR with either biweekly or monthly
pegloticase by their final visit in the OLE study.Table 3 Overall tophus complete response in patients
over time during the randomized controlled trialsa
Variables Pegloticase
biweekly
Pegloticase
monthly
Placebo
(n = 62) (n = 64) (n = 29)
Week 13
Patients with evaluable
tophi at visit, n
46 48 25
CR, n (%) 10 (22) 4 (8) 0
P valueb 0.011 0.292 –
Week 25
Patients with evaluable tophi
at visit, n
40 39 24
CR, n (%) 18 (45) 10 (26) 2 (8)
P valueb 0.002 0.110 –
Final visitc
Patients with evaluable tophi, n 52 52 27
CR, n (%) 21 (40) 11 (21) 2 (7)
P valueb 0.002 0.200 –
aCR, complete response. bPegloticase groups versus placebo for CR. cFinal visit
includes data from the patient’s final visit, whenever it occurred, for all
evaluable completers and noncompleters.Tophus size and response in the open-label extension
study
To assess the relationship between tophus size and res-
ponse in individual tophi, the TT-CR was evaluated ca-
tegorically by tophus area throughout the OLE period.
Numerically lower CR rates were associated with the lar-
gest tophi in both pegloticase groups (responders and
nonresponders). Among responders at the week 13 visit,
TT-CR rates were 76%, 54% and 8%, respectively, with
biweekly pegloticase and 90%, 86% and 17%, respect-
ively, with monthly pegloticase for tophi with a baseline
area smaller than 250 mm2, 250 to 750 mm2 and tophi
larger than 750 mm2. Corresponding values were 84%,
91% and 64% in the biweekly pegloticase group and 91%,
100% and 33% in the monthly pegloticase group for
small, medium and large tophi at the patient’s final visit.
A similar trend was observed in patients who received
open-label pegloticase either biweekly or monthly after
receiving placebo during the RCTs.
Discussion
A total of 73% of patients enrolled in the RCTs of
pegloticase had one or more tophi at baseline, a propor-
tion that is consistent with published study populations
defined by refractory gout [1,2]. Biweekly pegloticase—
the regimen approved in the United States and European
Union—resulted in complete resolution of at least one
target tophus without development of any new tophi or
progression of existing tophi in 22% of evaluable patients
at three months (the first protocol assessment) and in
45% of patients at six months. The benefit of pegloticase
on tophus burden increased with continued therapy
during the OLE study, particularly among patients who
responded to treatment with sustained PUA reductions
during the RCTs. By the final OLE visit, 59% of all patients
who received pegloticase during both the RCT and OLE
study achieved the best overall tophus response of CR.
Figure 3 Digital images showing complete resolution of tophi in two patients who received pegloticase biweekly. (A) Photograph of
patient 1 showing baseline tophus on the medial aspect of the patient’s right third distal interphalangeal (DIP) joint. (B) Photograph of patient 1
showing complete resolution of target tophus at week 13. Note also the reduction in the area of a large tophus on the third proximal
interphalangeal joint. (C) Photograph of patient 2 showing baseline tophi on the patient’s right thumb; on the second, third and fourth DIP joints
with ulcerations; and on the fifth proximal interphalangeal joint after six months of treatment with placebo in the randomized controlled trials.
(D) Photograph of patient 2 showing complete resolution of target tophi on four digits after 25 weeks of treatment with twice-monthly
pegloticase in the open-label extension study.
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RCT and the OLE study and showed a sustained urate-
lowering response (as defined by the primary endpoint of
the RCT), the overall tophus CR rate exceeded 80%.
The phase III and OLE studies of pegloticase em-
ployed a standardized method (CAPER) for assessing to-
phus size. This methodology, based upon the Response
Evaluation Criteria in Solid Tumors [18], was developed
to provide categorical scoring of tophus response cap-
tured by digital images of subcutaneous tophi. Multiple
methods of measuring tophi have previously been de-
scribed. These methods include direct physical tophus
measurements using tape measures [19] or calipers [11]
and imaging modalities such as ultrasonography [20],
magnetic resonance imaging [21-24], computed tomo-
graphy (CT) [21,25,26] or dual-energy CT [27,28]. A sys-
tematic review [29] of tophus assessment methods
aimed at determining their utility based on the Outcome
Measures in Rheumatology (OMERACT) filter (feasibi-
lity, truth and discrimination) concluded that physical
measurement techniques are most feasible and generally
fulfill the OMERACT filters. The CAPER method isdistinguished by the use of standardized digital pho-
tography, computer-assisted measurements, analysis by
an independent reviewer and a blinded, central reader
approach. Tophus responses in the pegloticase trials
paralleled treatment regimens, SUA levels and treatment
duration, thus demonstrating that the CAPER method
showed sensitivity to change and between-group sensi-
tivity [29]. Furthermore, CAPER provides several of the
advantages of advanced imaging modalities (raw data
storage and management, along with standardization
using central readers) and is cost-effective, easy to imple-
ment and patient-friendly. CAPER may be a valuable tool
for assessing tophus resolution in future clinical trials.
The rapidity of tophus resolution or reduction achieved
with pegloticase stands in contrast to data derived from
published trials of currently available urate-lowering
agents, although it should be noted that comparisons
between clinical trials with different populations and
measurement methods have well-documented limita-
tions. For example, in the pivotal phase III study evalua-
ting febuxostat versus allopurinol, median reduction in
tophus area (assessed by clinical examination) after
Table 5 Overall tophus complete response and target tophus complete response for patients in the open-label
extension studya
Visit during
OLE parameterb
Biweekly pegloticase in
RCT and continued
pegloticase in OLE
Monthly pegloticase in
RCT and continued
pegloticase in OLE
Placebo in RCT and
initiated pegloticase
in OLE
All patientsc
(n = 45) (n = 42) (n = 26) (N = 113)
Overall CR, n/N (% patients)
Week 13 visit 17 of 36 (47) 12 of 28 (43) 7 of 16 (44) 36 of 80 (45)
Week 25 visit 20 of 31 (65) 16 of 28 (57) 11 of 15 (73) 47 of 74 (64)
Week 53 visit 21 of 29 (72) 18 of 27 (67) 11 of 12 (92) 50 of 68 (74)
Week 77 visit 17 of 27 (63) 12 of 19 (63) 10 of 11 (91) 39 of 57 (68)
Week 101 visit 3 of 5 (60) 3 of 3 (100) 2 of 2 (100) 8 of 10 (80)
Final visit 23 of 39 (59) 20 of 34 (59) 13 of 21 (62) 56 of 94 (60)
TT-CR, n/N (% tophi) All target tophi (N = 357)
Week 13 visit 55 of 164 (34) 36 of 104 (35) 17 of 89 (19) 108 of 357 (30)
Week 25 visit 67 of 136 (49) 52 of 103 (50) 39 of 79 (49) 158 of 318 (50)
Week 53 visit 70 of 138 (51) 62 of 100 (62) 53 of 64 (83) 185 of 302 (61)
Week 77 visit 85 of 138 (62) 40 of 61 (66) 51 of 62 (82) 176 of 261 (67)
Week 101 visit 4 of 9 (44) 10 of 10 (100) 8 of 12 (67) 22 of 31 (71)
Final visit 90 of 164 (55) 68 of 121 (56) 49 of 105 (47) 207 of 390 (53)
aCR, complete response; OLE, open-label extension study; RCT, randomized controlled trial; TT-CR, target tophus complete response. bValues shown are number of
patients (n) with overall tophus response-CR/total number of patients (N) evaluated at the visit or number of target tophi (n) with CR/total number (N) of target
tophi evaluated at the visit. cThis population included all tophus-evaluable patients at each time point, both PUA responders and nonresponders, as defined by
the primary endpoint in the RCTs.
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66% with 120 mg of febuxostat and 50% with allopurinol
[30]. No significant change was seen in the number of
tophi over time in any of the treatment groups. Patients
enrolled in the febuxostat study were not defined by
chronic gout refractory to conventional therapy; rather,
their diagnosis of gout was based on the identification of
urate crystals in joint fluid, a tophus shown to contain
urate crystals and/or the presence of at least six clin-
ical, laboratory and X-ray characteristics described
according to the 1977 preliminary criteria for gout pub-
lished by the American Rheumatism Association [31].
To date, only pegloticase has demonstrated a signi-
ficant impact on tophus burden in controlled trials.
Prior to the approval of pegloticase, rasburicase, a
non-PEGylated recombinant uricase not indicated for
the treatment of gout, demonstrated tophus reduction
and/or resolution within a similar time frame as peglo-
ticase. In a small, retrospective, exploratory study, tophus
resolution and/or reduction was reported in two of four
patients with refractory tophaceous gout after six monthly
infusions of rasburicase [32].
The rapid tophus resolution seen with pegloticase
treatment may be explained by the profound and
sustained lowering of urate levels. In vitro experiments
have shown that the rate at which urate crystals dissolve
is proportional to the degree of urate lowering in the
surrounding fluid [33]. Investigators in a small serialultrasound study recently reported that evidence of sub-
acute crystal dissolution was seen only in patients with
sustained SUA levels of 6 mg/dl or lower [34]. In a sem-
inal study, Perez-Ruiz and colleagues observed an in-
verse relationship between mean SUA and the rate of
decrease in tophus size in gout patients who received
ULT [11]. Our data add to the implications of these fin-
dings by providing clinical evidence that tophus reso-
lution can be achieved in select patients within several
months if UA is reduced to levels well below what has
been achieved to date with oral agents. This was appar-
ent in the majority of patients showing sustained UA
lowering with biweekly pegloticase treatment and also in
the 26% of nonresponders, all of whom experienced ini-
tial but temporary reductions in UA. Tophus CR in such
transient responders to pegloticase treatment suggests
that UA reduction, even if short-lived, can be associated
with resolution of some tophi.
Limitations of the RCTs and the OLE study have been
described in their respective publications [16,35]. The
CAPER methodology, used as a tool for evaluating tophi
first reported in detail herein, has some limitations. First,
although CAPER incorporates standardization and rigor by
using bidirectional measurements and independent central
readers, assessment was based on a two-dimensional image
of a three-dimensional lesion. For example, the central
reader was not able to assess the firmness of tophi or pal-
pate borders. We believe that, because CR was the essential
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was not needed for our analysis. Second, tophi identified
by the central reader at baseline were not confirmed by
clinical examinations. For two patients in the placebo arm,
tophi were categorized as CR; it is likely that these lesions
were not tophi, but rather areas of cystic nongouty lesions
or joint inflammation that might have resolved after the
baseline measurement. Third, photographic analyses were
undertaken for the hands and feet and up to two other lo-
cations. Some patients had additional visible tophi at other
sites at baseline, and resolution of these “nontarget” tophi
was not captured. Thus, we may have underestimated the
number of patients with complete resolution of baseline
tophi.
Conclusions
Pegloticase, at the approved dosing regimen of 8 mg
every two weeks, produced sustained normalization of
PUA levels to less than 6 mg/dl in 42% of patients. This
improvement was associated with complete resolution of
at least one tophus in 22% of these patients after
13 weeks of blinded therapy and in 45% after 25 weeks
of therapy. Continued treatment with pegloticase
resulted in progressively greater numbers of patients
with a best overall tophus response of CR. This propor-
tion reached 59% of patients by their final visit in the
OLE study from among all patients who received
pegloticase during both the RCT and OLE study. Im-
portantly, tophus CR was achieved by more than 80% of
patients who maintained PUA levels lower than 6 mg/dl
for the duration of treatment. The results reported
herein support pegloticase as an important disease-
modifying therapy [16] for patients who have a signifi-
cant and refractory tophus burden.
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